Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF)

Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation medexus.com/en_US/investor…

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection medexus.com/en_US/investor…

Medexus Schedules Third Fiscal Quarter 2026 Conference Call medexus.com/en_US/investor…

For more than a decade IXINITY® has been a treatment option for those living with hemophilia B. FDA-approved in April 2015, we celebrate the 10th "Approve-iversary" of #IXINITY by looking back into the archives. Please see Full Prescribing Information at IXINITY.com

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares Read the full press release: medexus.com/en_US/news-med… #MedexusInc $MDP.CA $MEDXF

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares Read the full press release: medexus.com/en_US/investor… #MedexusInc $MDP.CA $MEDXF

Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection Read the full press release: medexus.com/en_US/news-med… #MedexusInc $MDP.CA $MEDXF

Medexus Schedules Second Fiscal Quarter 2026 Conference Call Read the full press release:medexus.com/en_US/investor… #MedexusInc $MDP.CA $MEDXF

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors medexus.com/en_US/investor…

Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection medexus.com/en_US/investor…

Medexus Schedules First Fiscal Quarter 2026 Conference Call medexus.com/en_US/investor…

GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026 medexus.com/en_US/investor…

Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States medexus.com/en_US/news-med…

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call medexus.com/en_US/news-med…

Review our April 17 news release for more information: medexus.com/en_US/news-med…

"This development is another important reimbursement milestone for Trecondyv® because we have now achieved public reimbursement of Trecondyv® in Canada's three most populous provinces, representing around three quarters of Canadians," said Richard Labelle, Medexus COO

The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Québec, or RAMQ, will now reimburse eligible claims made for Trecondyv®.

Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada medexus.com/en_US/investor…

Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection medexus.com/en_US/investor…

Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp. medexus.com/en_US/investor…